Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome

Rheumatology (Oxford). 2022 Aug 30;61(9):e277-e279. doi: 10.1093/rheumatology/keac222.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Behcet Syndrome* / drug therapy
  • Humans
  • Magnetic Resonance Imaging

Substances

  • Antibodies, Monoclonal, Humanized
  • secukinumab